SPCC1393.12 Antibody

What is SPCC1393.12 and what organism is it found in?

SPCC1393.12 is a Schizosaccharomyces pombe (fission yeast) specific protein. As indicated in the BioGRID database, it is classified as a "Schizosaccharomyces specific protein," meaning it is unique to this genus of yeast . S. pombe is a widely used model organism in molecular and cellular biology research, particularly for studying cell cycle regulation, DNA damage responses, and chromatin dynamics. Understanding SPCC1393.12's function requires specific tools like antibodies since this protein has no direct homologs in other model organisms such as budding yeast or mammals.

What is known about the cellular localization of SPCC1393.12?

According to the Gene Ontology (GO) Cellular Component annotation in the BioGRID database, SPCC1393.12 is localized to the cytoplasm . This localization was determined through direct experimental evidence (IDA - Inferred from Direct Assay), suggesting that techniques such as immunofluorescence microscopy with antibodies or fluorescent protein tagging have confirmed its cytoplasmic distribution. When designing experiments with SPCC1393.12 antibodies, this cytoplasmic localization should be considered for proper sample preparation, particularly when separating cellular fractions.

What interacting partners are known for SPCC1393.12?

The BioGRID database indicates that SPCC1393.12 has one documented interactor and one interaction . While the specific interacting partner is not detailed in the provided information, this suggests SPCC1393.12 may function as part of a protein complex or signaling pathway. When planning co-immunoprecipitation experiments with SPCC1393.12 antibodies, researchers should consider these known interactions and potentially explore whether stress conditions, similar to those affecting STY1 MAP kinase pathways in S. pombe, might influence these interactions .

How should I validate the specificity of a SPCC1393.12 antibody?

Validating antibody specificity for SPCC1393.12 requires a multi-faceted approach:

• Western blot analysis: Compare wild-type S. pombe with a SPCC1393.12 knockout strain. A specific antibody should detect a band of the predicted molecular weight in wild-type cells that is absent in the knockout.

• Epitope competition assay: Pre-incubate the antibody with excess purified epitope peptide before western blotting or immunoprecipitation. Signal reduction indicates specificity.

• Immunoprecipitation followed by mass spectrometry: Verify that SPCC1393.12 is the predominant protein identified in the immunoprecipitated sample.

• Alternative antibody comparison: If available, compare results using antibodies targeting different epitopes of SPCC1393.12.

For tagged versions of SPCC1393.12, western blotting techniques similar to those used for detecting Sty1 MAP kinase could be adapted, including sample preparation in which "a fraction of each IP was assayed by western blotting to ensure that equal quantities of protein were being isolated from the samples" .

What controls should I include when using SPCC1393.12 antibodies in western blot experiments?

For western blot analysis, researchers should follow protocols similar to those described for Sty1 detection, where "activated Sty1 was detected using the anti-phospho-p38 antiserum" with antibodies typically used at "a dilution of 1 in 1000" . Optimization of these dilution ratios may be necessary for SPCC1393.12 antibodies.

How can I optimize immunoprecipitation protocols for SPCC1393.12?

Optimizing immunoprecipitation (IP) of SPCC1393.12 requires careful consideration of several factors:

• Lysis buffer composition: Use a buffer that maintains protein-protein interactions while effectively lysing S. pombe cells. A starting point would be 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, with protease inhibitors.

• Antibody coupling: Consider covalently coupling the SPCC1393.12 antibody to beads (Protein A/G or magnetic) to prevent antibody co-elution with the target protein.

• Cross-linking considerations: For transient interactions, use formaldehyde or DSP (dithiobis(succinimidyl propionate)) cross-linking prior to cell lysis.

• Validation approach: As practiced with Sty1 MAP kinase experiments, "a fraction of each IP should be assayed by western blotting to ensure that equal quantities of SPCC1393.12 are being isolated from the samples" .

• Elution conditions: Optimize between harsh conditions (SDS, low pH) that may disrupt antibody and gentle conditions that maintain complex integrity.

For analyzing stress-responsive interactions, consider protocols that have been successful with stress-activated proteins like Sty1 MAP kinase, which is "recruited to stress-induced genes" .

What are the considerations for using SPCC1393.12 antibodies in chromatin immunoprecipitation (ChIP) experiments?

While SPCC1393.12 is primarily cytoplasmic , investigating potential chromatin associations requires specialized ChIP protocols:

• Crosslinking optimization: Test different formaldehyde concentrations (0.5-3%) and incubation times (5-20 minutes) to capture potential transient DNA-protein interactions.

• Sonication parameters: Optimize sonication conditions to achieve chromatin fragments of 200-500 bp, suitable for high-resolution mapping.

• Antibody specificity: Pre-clear lysates with normal IgG to reduce background and include an IgG control ChIP sample.

• Data analysis: For ChIP-seq data, normalize enrichment to input and employ appropriate statistical methods for peak calling.

When designing ChIP-seq experiments, consider methodologies similar to those mentioned in the study of heterochromatin spreading where "normalized counts per bin were obtained with the vst function" , which helps control for technical variation in sequencing depth.

How can I troubleshoot weak or absent signal when using SPCC1393.12 antibodies?

If experiencing detection issues with SPCC1393.12 antibodies, systematic troubleshooting should include:

• Protein expression level: SPCC1393.12 may be expressed at low levels under standard conditions. Consider:

  • Concentrating samples using TCA precipitation

  • Using enhanced chemiluminescence substrates

  • Extending primary antibody incubation time (overnight at 4°C)

• Extraction efficiency: The cytoplasmic localization requires effective cell lysis methods:

  • Test mechanical disruption methods (glass beads, French press)

  • Optimize lysis buffer composition with different detergents

• Epitope accessibility: The conformation of native SPCC1393.12 may mask epitopes:

  • Try denaturing conditions for western blots

  • Use different antibodies targeting distinct epitopes

  • Consider native vs. reducing conditions

• Technical parameters:

  • Increase antibody concentration (starting from 1:500 to 1:200)

  • Extend exposure times for western blots

  • Test different blocking agents (BSA vs. milk)

How can SPCC1393.12 antibodies be used to study potential stress responses in S. pombe?

Given the importance of stress responses in S. pombe biology, investigating SPCC1393.12's potential role could follow these methodological approaches:

• Expression analysis under stress conditions:

  • Expose S. pombe to various stressors (oxidative, osmotic, temperature)

  • Use SPCC1393.12 antibodies for western blotting to quantify expression changes

  • Compare with known stress-responsive proteins like Sty1 MAP kinase, which is "recruited to stress-induced genes"

• Localization changes:

  • Perform immunofluorescence under normal and stress conditions

  • Monitor potential translocation between cytoplasmic compartments

• Post-translational modification detection:

  • Use phospho-specific antibodies if phosphorylation sites are predicted

  • Employ 2D gel electrophoresis followed by western blotting to detect charge variants

• Protein-protein interaction dynamics:

  • Conduct co-immunoprecipitation experiments before and after stress

  • Compare interaction profiles under different stress conditions

• Chromatin association during stress:

  • Despite being primarily cytoplasmic , some proteins relocate during stress

  • ChIP experiments during stress might reveal conditional chromatin association

What genomic approaches can be combined with SPCC1393.12 antibodies for comprehensive analysis?

Integrating antibody-based techniques with genomic approaches provides deeper insights:

• ChIP-seq applications:

  • If SPCC1393.12 conditionally associates with chromatin, ChIP-seq can map genome-wide binding sites

  • Apply analytical approaches similar to those used in heterochromatin studies where researchers "segregate the central output of heterochromatin (gene silencing) from the spatial control of the reaction (spreading)"

• RIP-seq (RNA immunoprecipitation):

  • If SPCC1393.12 binds RNA, investigate associated transcripts

  • Optimize crosslinking for protein-RNA interactions

• Proteomics integration:

  • Combine immunoprecipitation with mass spectrometry

  • Compare interactome under different conditions

  • Quantify changes using SILAC or TMT labeling

• Single-cell approaches:

  • Adapt antibody-based flow cytometry to measure SPCC1393.12 levels in single cells

  • Correlate with other markers to identify subpopulations

These integrated approaches can help determine if SPCC1393.12 functions in pathways similar to those studied in the heterochromatin spreading research, which investigated "the genetic requirements for promotion and containment of heterochromatin spreading" in specific chromatin contexts .